ĐÁNH GIÁ KẾT QUẢ ĐIỀU TRỊ UNG THƯ BIỂU MÔ BUỒNG TRỨNG TÁI PHÁT KHÁNG PLATINUM BẰNG LIPOSOMAL DOXORUBICIN TẠI BỆNH VIỆN K GIAI ĐOẠN 2018 – 2021

Abstract

Objectives: To evaluate the treatment outcomes for patients with platinum-resistant recurrent epithelial ovarian cancer with liposomal doxorubicin and some adverse events the regimen. Patients and method: 30 patients with platinum-resistant recurrent epithelial ovarian cancer treated with liposomal doxorubicin at K Hospital from January 2018 to August 2021. Results: The initial stage of diagnosis is mainly stage III, and IV: 60%, 23.3%, respectively. All of  patients with CA125 elevation at the time of progression, recurrence. 53.3% partial response disease, 40% stable disease, 6.7% progression disease, 93,3%  of patients have clinical benefits. The response rate according to stage III, and IV were 50%, 28.5%, respectively. To the adverse events of liposomal doxorubicin: neutrophils, thrombocytopenia, mainly at grade 1, 2, no one had grade 3, 4. Hand-foot syndrome seen at grade 1, 2, vomiting, nausea mainly grade 1,  no cases grade 3, 4.